Emerging evidence also underscores the involvement of metabolic pathways in migraine pathogenesis, revealing novel therapeutic targets.37Through their anti-inflammatory and neuromodulatory actions, GLP-1 RAs may offer an additional mechanism for migraine control, particularly in cases with obesity, as it is a known risk factor for chronification. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.